A recent NORML analysis has revealed that over 4,000 scientific papers focusing on cannabis were published globally in 2024. This marks the fourth year that research output has reached this level.
Since 2014, over 35,000 cannabis-related studies have been released, according to NORML. These publications reflect an increasing emphasis on exploring the plant’s therapeutic benefits and the societal impacts of legalization laws.
Paul Armentano, NORML’s Deputy Director, shared insights in a blog post, noting that the past decade has seen an exponential rise in marijuana research. “Contrary to the belief that cannabis lacks sufficient scientific investigation, researchers have significantly deepened their understanding of cannabis, its active compounds, mechanisms, and its effects on users and society,” he stated. He further called on policymakers to shift their focus from uncertainties about marijuana to evidence-based discussions that reflect current knowledge.
NORML’s analysis involved a keyword search on PubMed.gov, a National Library of Medicine resource. The group reported that PubMed now lists over 49,500 scientific articles on cannabis, dating back to 1840. Interestingly, about 70% of these studies were published in the last decade, and over 90% have been added since 2002.
The research output for 2024 slightly trails the record set in 2022 when over 4,300 cannabis-related studies were published. However, the numbers still reflect a consistent upward trend compared to the previous decade, during which 32,000 studies were recorded.
Recent publications explore a variety of topics. For example, some studies highlight how cannabis legalization has reduced the rate of opioid overdose. Others discuss the plant’s ability to alleviate pain as effectively as morphine, and its role in improving the quality of life for patients with conditions like autism, epilepsy, and chronic pain.
Further research examines the effects of legalization on drug prescriptions. One study found that access to medical cannabis in Utah reduced opioid use among pain patients. Another revealed that incorporating marijuana into state prescription monitoring programs led to fewer prescriptions for narcotics.
Scientists have also delved into marijuana’s chemical components, including compounds like terpenes and minor cannabinoids. A study on cannabigerol (CBG) suggested it could help treat various conditions, including cancer and inflammation.
These studies represent just a fraction of the ongoing research into marijuana’s scientific, cultural, and legal dimensions as legalization continues to expand across the U.S., and federal reforms remain a topic of discussion in Congress. Industry actors like Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) hope that this growing body of scientific literature on marijuana helps to shape future drug policy in different jurisdictions.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN